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Tamoxifen has been the endocrine treatment of choice for all stages of oestrogen receptor positive breast cancer for 20 years and
the ﬁrst chemical therapeutic to be tested to reduce the incidence of breast cancer in high-risk women. It is now clear that the
oestrogen receptor is proving to be an invaluable target for the treatment and chemoprevention of breast cancer. The success of
tamoxifen clinically can be quantitated: 400 000 women are alive today because of the application of 5 years of adjuvant tamoxifen
therapy in node-positive and node-negative breast cancer. This advance has resulted in vigorous eﬀorts to reduce side-eﬀects and to
improve objective response rates by the rapid application of laboratory principles. Tamoxifen is known to have a mixture of oes-
trogen-like and anti-oestrogen actions so it is reasoned that completely anti-oestrogenic agents would enhance treatment response
rates while lowering the incidence of oestrogen-like side-eﬀects such as endometrial cancer and blood clots. A new pure anti-oes-
trogen, fulvestrant, that destroys the oestrogen receptor, is available after drug resistance to tamoxifen develops. The group of
drugs known as aromatase inhibitors block the production of oestrogens from androstenedione and testosterone in the body fat of
postmenopausal women. New agents such as anastrozole, exemestane, and letrozole have shown promise as new treatment mod-
alities for advanced breast cancer. Most importantly, the successful testing of anastrozole as an adjuvant treatment for breast
cancer has enhanced enthusiasm for the evaluation of aromatase inhibitors and selective oestrogen receptor modulators (SERMs)
to be tested as chemopreventives. SERMs express anti-oestrogenic actions in the breast but oestrogen-like actions in bone and
lower circulating cholesterol. This insight not only allowed the safe application of tamoxifen to well high-risk women to test the
worth of an ‘anti-oestrogen’ to prevent breast cancer, but also caused a paradigm shift in the strategy of chemoprevention. The
question was posed that if, tamoxifen prevents breast cancer but an added beneﬁt is the maintenance of bone density, why not
develop a drug to prevent osteoporosis or atherosclerosis that prevents breast cancer in the general population as a beneﬁcial side-
eﬀect? Raloxifene is the result of this new strategy to seek multifunctional medicines for women’s health. Raloxifene is currently
available for the treatment and prevention of osteoporosis but is being tested in high-risk postmenopausal women for the preven-
tion of breast cancer against tamoxifen in the study of tamoxifen and raloxifene (STAR trial) and for the prevention of coronary
heart disease (CHD) in a placebo-controlled trial in women at high risk for CHD called raloxifene use for the heart (RUTH).
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The breast is the leading site for cancer incidence and
the second most common site for cancer death among
US women [1]. As a result, treatment and chemo-
prevention have been the focus of laboratory work and
clinical trials for the past 30 years. However, as the pace
to introduce new treatment modalities has quickened, it
is perhaps valuable to reﬂect upon the origins of themost successful strategy that has propelled research
from the era of nonspeciﬁc chemotherapy to the present
era of targeted treatments. At the beginning of the 20th
century, Professor Paul Ehrlich was the ﬁrst to reason
that a parasite or cancer could be targeted selectively by
a chemical therapy to cure disease without harming the
host [2]. Even though a cure for cancer remained elu-
sive, he demonstrated a logical approach to a complex
problem: Identify a selective target, test a drug in the
laboratory and then conduct clinical studies.
In 1936, Professor Antoine Lacassagne suggested
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sensitivity to oestrogen, then the disease could be pre-
vented by developing a therapeutic antagonist to ‘‘pre-
vent the congestion of oestrone’’ in the breast [3].
However, there were no therapeutic antagonists of oes-
trogen at that time, nor was there a target for drug
design. Furthermore, there was little interest in treating
breast cancer with new hormonal drugs, and most of the
endocrinology research focused on understanding
reproduction. The ﬁrst non-steroidal anti-oestrogen,
MER25, was described by Lerner and co-workers in
1958 [4] and identiﬁed as a possible contraceptive. This
drug failed in clinical trial because the large doses
caused neurotoxicity [5], so drug discovery then swit-
ched to triphenylethylene-based compounds that resul-
ted ﬁrst in clomiphene and then tamoxifen [6,7].
Simultaneously, the nature of the target began to
evolve: In 1962, Jensen and Jacobson [8] demonstrated
that [3H]oestradiol bound to oestrogen target tissue
including uterus, vagina and pituitary gland in the
female rat. Further work conﬁrmed the oestrogen
receptor’s (ER) role as a nuclear protein and tran-
scripton factor [9–11]. More importantly for the appli-
cation of basic knowledge to cancer therapy, more than
60% of breast cancers were found to contain measur-
able levels of ER. In general, patients who are ER-
positive have a longer disease-free interval and longer
survival times than women with receptor-negative dis-
ease [12,13]. Furthermore, the responsiveness of breast
cancer to endocrine ablation and/or anti-oestrogen
therapy is now proven to correlate with the ER target
[7,14–16]. Thus, a research focus by the academic com-
munity working with industry, beginning in the early
1970s, facilitated the successful development of tamox-
ifen as a breast cancer treatment [7,17,18]. Subsequent
research has built on the knowledge of tamoxifen’s
actions and the enhancement of the eﬀectiveness of
agents that use the ER as a target.2. Selective modulation
The clinical pharmacology of non-steroidal anti-oes-
trogens is complex and cannot be described as simply a
blockade of oestrogen action and is now referred to as
selective oestrogen receptor modulation (SERM) to
describe the site-speciﬁc eﬀects [19]. Tamoxifen and the
other triphenylethylene antioestrogens bind with high
aﬃnity to tissues throughout the body. The high level of
protein binding results in drug accumulation and slow
excretion [20]. Tamoxifen functions through the ER
[21,22] but the biological eﬀects of oestrogen may be
mediated by two receptors, oestrogen receptor-a (ERa)
and oestrogen receptor-b (ERb) (Fig. 1). The cloning of
ERa in 1986 [10,23] focused research eﬀorts on the
existence of only one ER protein in all target tissues.
Ten years later, ERb was identiﬁed in the rat prostate[24] and in humans [25]. The two ERs share a conserved
structure with six functional domains, A–F. ERb is
homologous to ERa at the ligand binding domain
(58%) and DNA binding domain (95%). The remaining
domains are not well conserved [26]. The discovery of
ERb has advanced our understanding of oestrogen sig-
nalling and may explain responses to oestrogen in tis-
sues in which ERa is undetectable [27]. Furthermore,
the existence of ERa and b subtypes provides a possible
explanation for the tissue selectivity of SERMs
although knowledge of SERM action in breast cancer
and the development of drug resistance in the form of
‘tamoxifen stimulated growth’ is almost certainly tar-
geted to ERa exclusively (see Fig. 2).
The agonist/antagonist activity of the ER–tamoxifen
complex is determined by cell context. Tamoxifen func-
tions as an antagonist in most ER-positive breast
tumours, but displays a paradoxical agonist activity in
bone density [28–30] and serum lipid levels, and partial
agonist activity in the uterus [19,31] (Fig. 3). Tamoxifen
exhibits oestrogen-like eﬀects in postmenopausal
women, including a decrease in luteinising and follicle-
stimulating hormone [32]. Tamoxifen has been shown to
increase bone density in the lumbar spine, radius and
femur by 1–2% [30,33]. Several studies have also shown
that tamoxifen also has oestrogen-like eﬀects on serum
lipid proﬁles [34–36]. Low-density lipoprotein choles-
terol is reduced by approximately 15%, and high-den-
sity lipoprotein cholesterol is maintained. There is no
prospective clinical evidence that tamoxifen will reduce
the risk of coronary heart disease, but it is important to
state that with the ﬁnding that hormone-replacement
therapy (HRT) does not signiﬁcantly reduce the risk for
CHD [37] but, in fact, on balance is detrimental to
women’s health; there are opportunities in medicinal
chemistry to develop new selective medicines.
It is well known that tamoxifen produces a partial
agonist action in the human uterus [31,38]. The most
signiﬁcant ﬁnding is an increase in the stromal compo-
nent, rather than endometrial hyperplasia [39,40].
Tamoxifen does not increase the risk of endometrial
cancer in premenopausal women, but does increase the
risk by 3- to 4-fold in postmenopausal women [41].
Importantly, the stage and grade of endometrial cancers
observed in women taking tamoxifen are the same as
the general population [42].3. Drug resistance to tamoxifen
Although tamoxifen is classiﬁed as an anti-oestrogen
for the use as a breast cancer treatment, the action of
the drug is subverted by the molecular conﬁguration of
the cell that can convert tamoxifen from an antioestro-
gen to an oestrogen. Thus, tamoxifen-stimulated (resis-
tant) breast cancer growth can be demonstrated both in2 D.J. Bentrem et al. / EJC Supplements Vol 1 No. 1 (2003) 1–12
Fig. 1. The oestrogen receptor (ER) signal transduction pathway. Gene transcription is initiated with either a selective ERmodulator (SERM) or oestrogen
binding to the ER (a or b) which induces a conformational change in the receptor. After interaction with various corepressors (CoR) or coactivators (CoA),
the transcription unit binds either to an oestrogen-response element (ERE) in the promotor region of an oestrogen-responsive gene or through a protein/
protein interaction (fos and jun) at the AP-1 site. Gene transcription can produce either stimulatory or inhibitory signals depending on the target site.Fig. 2. Integrated mechanism for the target site-speciﬁc action of selective ER modulators (SERMs) in breast or uterine cancer. The two extremes of
antioestrogenic or full oestrogenic actions are shown. Oestrogen-like actions could occur in cells expressing an excess of coactivators (CoAs) and/or
a decrease in corepressors (CoRs). The charged surface of a tamoxifen oestrogen receptor (ER) complex at AF2b prevents CoR binding. The oes-
trogenic action would be ampliﬁed by surface signaling with dimers of epidermal growth factor receptor (EGFR) and HER2/neu activating tyrosine
kinases (tks). The phosphorylation cascade can activate AF-1 on ERa directly or activate the excess of CoAs in a high ER environment. Reduced
levels of ER prevent the signal transduction pathway and promote antioestrogenic actions in a surface silent cell.D.J. Bentrem et al. / EJC Supplements Vol 1 No. 1 (2003) 1–12 3
the laboratory [43] and clinically in advanced breast
cancer [44].
A molecular model of tamoxifen and SERM action
during the development of drug resistance is now emer-
ging. Indeed, the extensive literature on the molecular
pharmacology of tamoxifen can be used to evaluate the
critical associations noted in clinical studies. Knowledge
of the triumvirate of ER, cell-surface signalling and
coactivators has been used previously to understand the
actions of SERMs (Fig. 2). Shang and Brown [45] have
recently shown that the concentration of an ER coacti-
vator (SRC-1) can enhance some ER-mediated gene
activation in endometrial cancer cells where tamoxifen
has oestrogen-like eﬀects. Levels of SRC-1 were tran-
siently increased or decreased in cells to modulate gene
activation by tamoxifen. However, Brown’s group has
also shown that cell-surface signalling can enhance the
breast cancer-related coactivator, SRC-3 phosphoryla-
tion and ER activation [46]. If the triumvirate of ER
level, HER2/neu expression and coactivator SRC-3 is
critical for cancer-cell survival during resistance to
tamoxifen, there needs to be an innate support
mechanism so that the signal transduction pathways are
coordinated to work in harmony. Arguably, the most
important component of tamoxifen-stimulated growth
is the ER. Anti-oestrogen binding to the ER increases
the transcription of the HER2/neu gene by releasing ER
coactivators from the oestradiol ER complex. These
coactivators then activate the HER2/neu promoter [47].
This cancer-cell survival system facilitates cell-surface
signalling and, ultimately, subverts tamoxifen’s actionthrough the phosphorylation of coactivators [46] and ER
(Fig. 2). Importantly, tamoxifen ER complexes have a
built-in mechanism to enhance their own long-term sur-
vival so that the complex can become promiscuous at
gene targets within the cell. The oestradiol–ER complex
is a powerful intracellular messenger that needs to be
ubiquitinised and destroyed rapidly by the proteosome.
However, the tamoxifen–ER complex tends to accumu-
late in the cell because of poor ubiquitinisation [48]. The
destruction process is controlled through a region
around D538 that is exposed to and apparently impaired
on the surface of the tamoxifen–ER complex [49].
Apparently, the coactivator SRC-3 is a rate-limiting
factor for oestrogen-dependent growth of MCF-7 breast
cancer cells in culture [50]. Nevertheless, oestrogen cau-
ses a reduction in SRC-3 mRNA but anti-oestrogens
cause an increase in SRC-3 mRNA [51] through an
increase in transforming growth factor a (TGFa), so a
complete self-regulated system is in place for breast
cancers to acquire resistance eventually. The hypothesis
has recently been supported using retrospective clinical
samples. Patients with ER-positive breast cancers, high
HER2/neu and elevated SRC-3 were noted to fail
adjuvant tamoxifen rapidly [52].4. Alternative treatments for oestrogen blockade: pure
anti-oestrogens and aromatase inhibitors
The question must be asked whether the physician can
subvert the power of the triumvirate by the judiciousFig. 3. Site-selective eﬀects of adjuvant tamoxifen therapy.4 D.J. Bentrem et al. / EJC Supplements Vol 1 No. 1 (2003) 1–12
use of new approaches to endocrine therapy. There are
two approaches; either the ER target can be blocked
and prematurely destroyed by a pure anti-oestrogen
[53], or the synthesis of oestrogen can be prevented with
an aromatase inhibitor so no oestradiol ER complex
will form.
‘Pure’ anti-oestrogens are, by deﬁnition, anti-oestro-
genic in all target tissues [53] because there is destruction
of the ER in target sites [48,54,55]. The pure anti-oestro-
gens are eﬀective in laboratory models as second-line
treatment for tamoxifen-stimulated breast [56,57] and
endometrial cancer [58,59]. Clinically, it must be admi-
nistered by intramuscular injection because of low oral
potency. Following successful phase II studies [60], ran-
domised trials were initiated comparing fulvestrant
(Faslodex1) with another hormonal therapy, the aro-
matase inhibitor anastrozole, in-patients with tamox-
ifen-refractory advanced breast cancer. Fulvestrant and
anastrozole are equivalent treatments [61,62]. Further
large randomised clinical trials are underway and will
address remaining questions regarding eﬀects of long-
term therapy on bone mineral density and serum lipid
proﬁles.
After menopause, circulating oestrogen levels drop to
about 20% of those of premenopausal women and, in
the absence of cyclic ovarian function, remain at steady-
state concentrations. In postmenopausal women, oes-
trogens (oestrone and oestradiol) are produced mainly
through aromatisation of androgen precursors (andros-
tenedione and testosterone) [63], particularly in breast
tissue where oestrogen concentrations are higher than
plasma concentrations. Immunohistochemical analysis
and in situ hybridisation techniques have shown that the
aromatase and precursor mRNA are expressed in the
epithelial cells of the terminal ductal lobular units and
in the surrounding stromal cells of normal breast tissue
[64]. Oral aromatase inhibitors have been shown to
reduce aromatase activity and oestradiol concentrations
within tumoral tissue of patients with primary breast
cancer [65].
Third-generation aromatase inhibitors are divided
into steroidal suicide inhibitors, type I (exemestane),
which bind to the aromatase enzyme and destroy func-
tion through covalent interaction and nonsteroidal oral
inhibitors, and type II (anastrozole and letrozole),
which are competitive inhibitors of aromatase action.
Whereas tamoxifen, ovarian ablation, and second-gen-
eration aromatase inhibitors reduce oestrogen eﬀects to
some degree, only third-generation aromatase inhibitors
reduce circulating oestrogens to nearly undetectable
levels without an eﬀect on the formation of adrenal
corticosteroids or aldosterone.
All of the third-generation oral aromatase inhibitors
have now been tested in phase III trials as second-line
treatment of postmenopausal hormone-dependent
breast cancer [66]. They have shown clear superioritycompared with the conventional therapies and are
therefore considered (at least) established second-line
hormonal agents. Exemestane is an orally active ster-
oidal aromatase inhibitor that has demonstrated eﬃcacy
in the treatment of postmenopausal patients with
advanced breast cancer [67,68]. This compound exhibits
a good tolerability and safety proﬁle, which may result
from its highly selective mechanism of action. Exemes-
tane binds irreversibly to the aromatase enzyme causing
inactivation of the enzyme. Exemestane is a potent
inhibitor of aromatisation-reducing oestrogen synthesis
in vivo by greater than 97% [69]. The most frequently
reported drug-related adverse events are hot ﬂushes,
nausea and fatigue, which are consistent with the oes-
trogen-suppressive eﬀects of the drug [70]. Discontinua-
tion due to adverse events is rare. Exemestane is a safe
and well-tolerated alternative for the treatment of post-
menopausal patients with advanced breast cancer.
Anastrozole is the ﬁrst third-generation aromatase
inhibitor for the treatment of advanced breast cancer. It
inhibits the aromatase enzyme by competitively binding
to the haeme of the cytochrome P450 subunit of the
enzyme, resulting in a reduction of oestrogen biosynth-
esis. Two studies with the selective aromatase inhibitor
anastrozole versus tamoxifen for advanced breast can-
cer were recently published [71,72]. In both studies,
response rates were similar. In the North American
study [71], time to progression (TTP) was in favour of
anastrozole (median TTP of 11.1 months versus 5.6
months for anastrozole and tamoxifen). In the larger,
mainly European study, 668 patients were randomised
to receive either anastrozole 1 mg once daily or tamox-
ifen 20 mg once daily, and TTP was similar for both
treatments supporting the use of anastrozole as an
alternative treatment to tamoxifen in postmenopausal
women with advanced breast cancer [72]. Side-eﬀects
included nausea 15%, hot ﬂashes 12%, arthralgias
in 10–13% [73] and vaginal dryness 2%.
Letrozole, another potent selective aromatase inhi-
bitor, has shown eﬃcacy as a second-line therapy of
advanced breast cancer in postmenopausal women after
tamoxifen has failed [74,75]. In a recent trial as ﬁrst-line
therapy for postmenopausal women with advanced
breast cancer, letrozole was as eﬀective as tamoxifen
with a longer time to progression (41 weeks versus 26
weeks) [76]. A small pilot study has also looked at
letrozole in the neoadjuvant setting. In a series of 24
patients with large operable breast cancer, letrozole was
eﬀective in reducing tumour volume, allowing all
patients to have breast-conserving surgery [77].
A lower risk of thromboembolic complications or vagi-
nal bleeding associated with anastrozole or letrozole is
seen when compared with tamoxifen [71,72,76]. Given this
aspect of the improved safety proﬁle, the US Food and
Drug Administration has approved both drugs for use as
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women. However, eﬀects on bone density and serum
lipids remain in question with long-term therapy. Pre-
liminary data from an EORTC study which randomised
122 postmenopausal patients with metastatic breast
cancer to tamoxifen or exemestane found little negative
impact of the oral aromatase inhibitor on serum lipids
[78]. The role of aromatase inhibitors in premenopausal
breast cancer in combination with chemotherapy and
gonadotropin-releasing hormone are areas of future
exploration.5. Adjuvant anastrozole
The recent publication of the ATAC (Arimidex versus
tamoxifen and the combination) trial demonstrates that
an aromatase inhibitor, as a single adjuvant agent, is
superior to tamoxifen or the combination in ER-posi-
tive patients. The ATAC trail clearly demonstrates an
increase in DFS for anastrozole (1 mg) over tamoxifen
(20 mg) during the early analysis at 2.5–3 years of
treatment [79]. Most importantly, there are reductions
in blood clots, vaginal discharge and endometrial cancer
in the anastrozole alone arm compared with either the
tamoxifen alone or the combination. Even though there
is a small, but signiﬁcant, number of recurrences in the
anastrozole arm compared with tamoxifen, it will be
important to establish which patients fail tamoxifen—in
other words, which patients will beneﬁt from anastro-
zole. One line of reasoning focuses upon the triumvirate
of cell-surface signalling, coactivators and the ER. A
neoadjuvant study demonstrates that patients with high
cell-surface signalling (HER2/neu/EGFR) are less likely
to respond to tamoxifen [80]. Additionally, the recent
report by Osborne [52] indicates that 10% of patients
who are HER2/neu-positive with high levels of SRC-3
do not respond to tamoxifen. It is possible that these are
the patients who respond to anastrozole by impairing
signal transduction because the ER is unoccupied dur-
ing therapy with an aromatase inhibitor.6. Prevention trials
Oestrogenic hormones are considered to be the pro-
moter of initiated breast cells and to act over many
years to increase the tumour-cell population. Since the
promotional stage is characterised by reversibility, there
has been great interest in preventing the consequences of
prolonged, unopposed oestrogenic stimulation of the
breast. Laboratory studies laid the foundation for
chemoprevention: tamoxifen prevented carcinogen-
induced mammary cancer in rats [81,82]. Subsequently,
the decrease in contralateral breast cancers during
tamoxifen administration for adjuvant therapy [16], and a
favourable toxicity proﬁle in clinical practice, suggestedthe drug could be evaluated in women at risk for breast
cancer.
Four studies have addressed the prevention question,
the Royal Marsden Pilot Study [83], the Italian
Tamoxifen Prevention Study [84–86], the National Sur-
gical Adjuvant Breast and Bowel Project (NSABP) [41]
and the IBIS study [87]. The Marsden study, which
enrolled 2494 high-risk women, was designed as a pilot
toxicology study to serve as a basis for a nationwide
clinical trial in Britain that originally planned to recruit
20 000 high-risk women. This did not occur, but the
plan evolved into the IBIS study (see later). The Mars-
den Study evaluated the problems of accrual, acute
symptomatic toxicity, compliance and safety for the use
of tamoxifen in a larger trial; however, the Marsden
study was also analysed for breast-cancer incidence. No
diﬀerence in the incidence of breast cancer was observed
between groups, with 34 carcinomas in the tamoxifen
group and 36 in the placebo group. There is no satis-
factory explanation why the tamoxifen arm failed to
show a decrease in breast-cancer incidence. The authors
suggest that perhaps there was a high population of
BRCA-1 and -2 carriers that possibly are hormone
unresponsive. There is limited data on the responsive-
ness to tamoxifen treatment of genetic breast cancer
[88]. In a case–control study, Narod and colleagues [89]
found tamoxifen protected against contralateral breast
cancer for carriers of BRCA1 mutations (Odds Ratio
(OR) 0.38, 95% Conﬁdence Interval (CI) 0.19–0.74) and
for those with BRCA2 mutations (OR 0.63, CI
0.20–1.50). In women who used tamoxifen for 2–4
years, the risk of contralateral breast cancer was
reduced by 75%.
The Marsden study has provided invaluable informa-
tion about the eﬀects of tamoxifen in healthy women,
but we believe the study was underpowered and not
designed to answer the question of whether tamoxifen
prevents breast cancer.
The Italian study evaluated 5408 low-risk women
beginning in October 1992 until December 1997 [84].
Originally, the study intended to enrol 20 000 volunteers
without risk factors, but ended prematurely due to poor
recruitment and compliance. Prior to enrolment, women
were required to have had a hysterectomy to obviate
concerns about a possible increased risk of endometrial
carcinoma. There was no requirement that participants
be at risk for breast cancer and, in fact, 47% had a
reduced risk of breast cancer, having had pre-
menopausal oophorectomy with hysterectomy. The
incidence of breast cancer did not diﬀer between groups,
with 34 cases in the tamoxifen group and 45 in the pla-
cebo group with a median follow-up of 76 months [86].
Tumour characteristics, including size, grade, lymph
node status and receptor status, did not diﬀer between
groups. The results of this study can be explained by the
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young age, and the small number of participants who
completed 5 years of tamoxifen treatment. However,
high-risk groups for ER-positive breast cancer could be
predicted and tamoxifen was found to be extremely
eﬀective as a chemopreventive [86]. The conclusion that
can be drawn from this study is that the beneﬁt of
tamoxifen is likely to be small in women with an aver-
age or decreased risk of breast cancer. In contrast,
women who are carefully preselected to be at elevated
risk can anticipate eﬀective chemoprevention. One
important ﬁnding is that, in the population of women
who took oestrogen-replacement therapy, tamoxifen
prevented the development of breast cancer. Studies are
planned in Italy to address this interesting ﬁnding and
evaluate the value of an HRT/SERM combination.
The NSABP Protocol P-1 was the ﬁrst completed
prospective, randomised clinical trial to support the
hypothesis that tamoxifen can prevent breast cancer in a
high-risk population. This clinical trial opened in May
1992 and closed 5 years later after accruing 13 388 high-
risk women, a group suﬃcient to answer the prevention
question. Those eligible included women over the age of
60 years, or women over 35 years whose 5-year risk of
developing breast cancer, as predicted by the Gail
model [90], was equal to that of a 60-year-old woman.
Tamoxifen administration reduced the risk of invasive
and non-invasive breast cancers by approximately 50%
in all age groups [41]. A subset analysis of women at
risk with the diagnosis of lobular carcinoma in situ
demonstrated a 56% reduction of invasive cancers. The
most dramatic reduction, 86%, was seen in women at
risk due to atypical hyperplasia. As expected, tamoxifen
aﬀected only the incidence of ER-positive tumours,
which were overall reduced by 69% per year. The inci-
dence of ER-negative tumours in the tamoxifen group
did not diﬀer signiﬁcantly from that of the placebo
group. Tamoxifen reduced the incidence of invasive
cancers of all sizes, but the greatest diﬀerence was seen
in tumours 42.0 cm in size. Tamoxifen reduced the
incidence of both node-positive and node-negative
breast cancer. The beneﬁcial eﬀects were observed for
each year of follow-up, with 33% reduction after 1 year,
and 69% reduction after 5 years. The absolute number
of breast-cancers in the control group also provided a
means to validate the Gail model [91] which, despite
some limitations, is able to provide useful information
on breast-cancer risk for women who plan to participate
in annual mammographic screening programs.
The most recent trial to report results with the use of
tamoxifen as a chemopreventive is the IBIS trial [87]. A
total of 7152 high-risk women aged between 35 and 70
years were randomised to 5 years of tamoxifen (20 mg)
or placebo. There was a 32% risk reduction for breast
cancer, but the authors cautioned about the use of pro-
phylactic tamoxifen in women at high risk of throm-
boembolic disease, especially after surgery [87].These data have driven the evolution of ideas from
the treatment of breast cancer toward preventive ther-
apeutics. Although tamoxifen substantially reduces the
risk of breast cancer among women at higher than
average risk for the disease, it has not been proved that
the risk beneﬁts of tamoxifen would beneﬁt the average
risk population of women. Nevertheless, current strate-
gies are addressing the concern.7. Raloxifene as a chemopreventive
Raloxifene, a second-generation SERM, has a high
binding aﬃnity for the ER [92,93], and exhibits potent
anti-oestrogenic activity. There has been limited clinical
experience with raloxifene in the treatment of breast
cancer; however, the rationale for the use of raloxifene
as a treatment of osteoporosis with the side-eﬀect of
breast-cancer prevention was ﬁrst described in 1990
[94].
Raloxifene reduces the incidence of N-nitroso-
methylurea-induced tumours if given after the carcino-
gen [95,96], but before the appearance of palpable
tumours. However, as anticipated with a short biologi-
cal half-life secondary to rapid phase II metabolism and
poor bioavailability [97], raloxifene is not superior to
tamoxifen at equivalent doses [95].
Raloxifene maintains bone density in ovariectomised
rats [29,98–103]. In studies of postmenopausal women,
raloxifene acts as a partial oestrogen agonist in bone,
increasing bone density by 2.4% in the lumbar spine
and the total hip [104].
Raloxifene produces a signiﬁcant decrease in low-
density lipoprotein cholesterol, with maintenance of tri-
glyceride and high-density lipoprotein levels [104–106].
Laboratory data in the rabbit strongly support the value
of raloxifene to prevent atherosclerosis [107]. However,
data in primates fed high-cholesterol diets did not show
any beneﬁt [108]. A prospective, randomised clinical
trial is in place to address the question of whether
raloxifene has merit for risk reduction of coronary heart
disease in high-risk postmenopausal women. The study,
Raloxifene Use for the Heart (RUTH), has randomized
10 000 high-risk women to placebo or 60 mg of ralox-
ifene daily for 5 years. Results should be available by
2005 [109]. Venous thromboembolism is a serious
adverse eﬀect associated with raloxifene (3.32 events per
1000 woman-years) [110]. The magnitude of the RR is
similar to that observed with both hormone replacement
therapy [111] and tamoxifen [41].
A current evaluation in women screened to ensure the
absence of pre-existing endometrial abnormalities shows
that raloxifene, unlike oestrogen, does not increase
endometrial thickness [112]. There is no clinical evi-
dence to date to suggest that raloxifene increases the
risk of endometrial cancer.D.J. Bentrem et al. / EJC Supplements Vol 1 No. 1 (2003) 1–12 7
8. MORE trial
Based on the hypothesis that raloxifene could reduce
the incidence of breast cancer as a beneﬁcial side-eﬀect
of the prevention of osteoporosis [94], placebo-con-
trolled trials with raloxifene were started in the early
1990s. The Multiple Outcomes of Raloxifene Eval-
uation (MORE) has randomised 7704 postmenopausal
women with osteoporosis and no history of breast or
endometrial cancer to placebo, 60 or 120 mg raloxifene
daily. Raloxifene reduces the incidence of vertebral
fractures by 30% in postmenopausal women with
osteoporosis taking 60 mg daily [113], but the risk of
non-vertebral fractures did not diﬀer signiﬁcantly. Ana-
lysis of results at 3 years [114] and 4 years [110], con-
ﬁrmed a sustained 72% risk reduction of invasive breast
cancer. As noted in the tamoxifen study, raloxifene
reduces the incidence of ER-positive breast cancer and
has no eﬀect on the incidence of ER-negative breast
cancer. This study gave further evidence that increased
lifetime oestrogen exposure increased breast-cancer risk.
Raloxifene therapy reduced breast-cancer risk regard-
less of lifetime oestrogen exposure, but the reduction
was greater in those with higher lifetime exposure to
oestrogen [115]. The longer-term eﬀects of raloxifene 60
mg/day on reducing the incidence of breast cancer in
postmenopausal women will be evaluated in the Con-
tinuing Outcomes Relevent to Evista1 (CORE) trial,
which will follow the incidence of breast cancer in a
subset of the MORE cohort for an additional 4 years.9. STAR trial
The widespread acceptance of the worth of raloxifene
for breast cancer prevention depends on the results of
the Study of Tamoxifen And Raloxifene (STAR) trialthat will be completed between 2005 and 2007 (Fig. 4).
The primary aim of the STAR trial is to determine
whether long-term raloxifene therapy is as eﬀective as
tamoxifen in prevention of invasive breast cancer in
postmenopausal women identiﬁed as high risk. A sec-
ondary goal is to compare the net eﬀect of raloxifene
and tamoxifen with respect to cardiovascular disease,
fracture incidence and general toxicities. It is clear that
the activation or suppression of various target sites
around a woman’s body is similar for tamoxifen and
raloxifene, but an evaluation of the overall comparative
beneﬁts of the agents will provide an important new
clinical database for raloxifene in postmenopausal
women. The goal is to recruit 22 000 high-risk post-
menopausal women. As of early 2003, more than 15 000
volunteers had been randomised.10. No oestrogen at all for prevention
One of the early positive results in the ATAC trail is
the ﬁnding that anastrozole is superior to tamoxifen in
reducing the risk of contralateral breast cancer [79].
Plans are in place to exploit these early observations
(IBIS 2) with the aim of testing whether anastrozole will
reduce the incidence of breast cancer in normal-risk
postmenopausal women. The goal is to improve on the
safety proﬁle of tamoxifen but with further reductions
in the incidence of breast cancer. Clearly, these are
important studies but the long-term beneﬁts will need to
be balanced against the reductions in bone density,
osteoporotic fractures, CHD and Alzheimer’s disease.11. Closing the circle
What is to be done, in the future, when all of the
endocrine therapies have been used sequentially in the
ER-positive patient and there are no further responses?
What are the consequences of prolonged oestrogen
deprivation on the evolution of tumour biology?
Remarkably, a recent clinical report suggests that oes-
trogen therapy can produce signiﬁcant responses in
patients with antihormone resistant disease [116].
Indeed, this clinical situation has been modelled in the
laboratory and it appears that drug resistance to
tamoxifen therapy evolves ﬁrst through a phase (phase
1) where either tamoxifen or oestrogen can induce
breast-tumour growth (this explains the eﬃcacy of aro-
matase inhibitors after tamoxifen failure) [43] but then
in phase II of tamoxifen drug resistance, after 5 years of
treatment, oestrogen is a tumoricidal agent, even at
physiologic levels [117]. Similarly, breast-cancer cells
that are oestrogen-deprived for prolonged periods grow
spontaneously, but low concentrations of oestrogen
now induce apoptosis [118]. Clearly, there are clues toFig. 4. The study of Tamoxifen And Raloxifene (STAR) trial
design—22 000 women are being randomized to either 5-year treat-
ment with tamoxifen or raloxifene to determine whether long-term
raloxifene therapy is as eﬀective for the prevention of invasive breast
cancer in postmenopausal women identiﬁed as high risk.8 D.J. Bentrem et al. / EJC Supplements Vol 1 No. 1 (2003) 1–12
the evolving tumour biology of breast cancer that
should be incorporated into clinical trials but, before
this occurs, the mechanism of action of oestrogen to
induce apoptosis needs to be thoroughly investigated.
Since tamoxifen again becomes an anti-oestrogen follow-
ing the tumoricidal actions of oestrogen in tamoxifen-
resistant breast cancer [117], these data suggest that
hormonal scheduling may be able to maintain patients
indeﬁnitely before chemotherapy is considered.Acknowledgements
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